AI model risk management
AI model risk management in Healthcare & Life Sciences is now a direct compliance obligation, not a voluntary framework exercise. The U.S. Food and Drug Administration's finalized guidance on AI-enabled medical devices and the U.S. Department of Health and Human Services Office for Civil Rights position on algorithmic bias in clinical decision support have put model governance squarely inside regulatory scope. European Medicines Agency expectations for AI transparency in drug development add a third vector that multinational life sciences firms cannot ignore.
Watch
- FDA's action plan for AI/ML-based software as a medical device: predetermined change control plans
- HHS OCR algorithmic bias enforcement posture under Section 1557 of the ACA
- EMA reflection paper on AI in GxP-regulated activities and audit trail requirements
- Vendor accountability gaps: how regulators expect third-party model liability to be documented
- State-level AI bills in California and Colorado with healthcare carve-ins moving toward enforcement
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to ai model risk management will appear here as they are published.